We are live on
!
Find out more
State Street SPDR S&P Biotech ETF
274 hedge funds and large institutions have $2.17B invested in State Street SPDR S&P Biotech ETF in 2016 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 75 increasing their positions, 72 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
196% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 28
21% more funds holding
Funds holding: 227 → 274 (+47)
4% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 72
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
28% less call options, than puts
Call options by funds: $793M | Put options by funds: $1.1B
29.78% less ownership
Funds ownership: 118.69% → 88.91% (-30%)
30% less capital invested
Capital invested by funds: $3.11B → $2.17B (-$946M)
Holders
274
Holders Change
+47
Holders Change %
+20.7%
% of All Funds
6.85%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
83
Increased
75
Reduced
72
Closed
28
Calls
$793M
Puts
$1.1B
Net Calls
-$307M
Net Calls Change
+$11.3M
Top Buyers
Top Sellers
| 1 |
Citigroup
New York
|
-$275M |
| 2 |
Goldman Sachs
New York
|
-$258M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$99.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$95.3M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$92.9M |
